Kasi, Anup

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Randomized Phase III trial of Pegvorhyaluronidase Alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma

Van Cutsem, E., Tempero, M. A., Sigal, D., Oh, D.-Y., Fazio, N., Macarulla, T., Hitre, E., Hammel, P., Hendifar, A. E., Bates, S. E., et al. (2020) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 499

608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

Park, W., Kasi, A., Spira, A. I., Berlin, J. D., Wang, J. S., Herzberg, B., Kuboki, Y., Kitano, S., Pelster, M., Goldman, J. W., et al. (2024) · Annals of Oncology

Protein Degradation and InhibitorsPancreatic and Hepatic Oncology Research

Cited by 46

Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.

Tolcher, A. W., Park, W., Wang, J. S., Spira, A. I., Janne, P. A., Lee, H.-J., Gill, S., LoRusso, P., Herzberg, B., Goldman, J. W., et al. (2023) · Journal of Clinical Oncology

Protein Degradation and InhibitorsPancreatic and Hepatic Oncology Research

Cited by 33